Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
- Steven F L van Lelyveld
- Julia Drylewicz
- Maaike Krikke
- Ellen M Veel
- Sigrid A Otto
- Clemens Richter
- Robin Soetekouw
- Jan M Prins
- Kees Brinkman
- Jan Willem Mulder
- Frank Kroon
- Ananja Middel
- Jori Symons
- Annemarie M J Wensing
- Monique Nijhuis
- José A M Borghans
- Kiki Tesselaar
- Andy I M Hoepelman
DOIAbstract
The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients.Double-blind, placebo-controlled, randomized trial.Major inclusion criteria were 1. CD4+ T-cell count <350 cells/μL while at least two years on cART or CD4+ T-cell count <200 cells/μL while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients were randomized to add maraviroc...
Add to ORKG